



## *Curriculum Vitae*

**Richard Gillespie Diethelm, M.D.**  
**Alabama Clinical Therapeutics, LLC**  
**52 Medical Park East Drive, Suite 203**  
**Birmingham, Alabama 35235**

**Telephone** (205) 833-2228  
**Fax** (205) 833-6225

### **Additional Offices**

Neurology East  
48 Medical Park East Drive, Suite 351  
Birmingham, Alabama 35235

### **Education**

2004 - 2007 University of Alabama  
Department of Neurology, Resident Physician  
Birmingham, Alabama

2003 – 2004 University of Alabama  
Department of Medicine, Internship  
Birmingham, Alabama

1999 - 2003 University of Mississippi  
School of Medicine  
University, Mississippi

1997 Millsaps College  
Bachelor of Science in Biology and Minor in Chemistry  
Jackson, Mississippi

1994 Millsaps College  
Bachelor of Arts in Religious Studies  
Jackson, Mississippi

### **Professional Work Experience:**

2013–Present Investigator  
Alabama Clinical Therapeutics, LLC  
Birmingham, Alabama

2007-2013 Neurology East, self employed  
Privileges at St. Vincent's East Hospital

**Professional Work Experience (continued):**

2004-2007      University of Alabama  
                    Department of Neurology  
                    Resident Physician  
                    Birmingham, Alabama

**Honors / Awards Medical School:**

Argus Award – Best Neurology Resident (2004-2005)  
Best Preceptor Award  
Family Practice Residency  
St. Vincent's East Hospital, 2007

**Research Experience:**

Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on XXX once daily or treated with another approved disease-modifying therapy

A Study of Three Doses of XXX Compared to Placebo in the Acute Treatment of Migraine: A randomized, double-blind, placebo-controlled parallel group study

An Open-label, Long-term, Safety Study of XXX in the Acute Treatment of Migraine

A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine


Open-label Study of Safety and Tolerability of Chronic Intermittent Usage for 24 or 52 Weeks of Intranasal XXX Administered using the XXX Precision Olfactory Delivery (POD) Device [XXX] in Patients with Migraine Headache Stop XXX Trial (Safety and Tolerability of POD-DHE)

A Multicenter, Randomized, Double-Blind, Comparator-Controlled, Placebo-Controlled Study to Assess the Efficacy and Safety of Oral XXX in the Treatment of Acute Migraine Pain, With or Without Aura, and the Prevention of Migraine-Associated Nausea and Vomiting (MANV)



---

**Richard Gillespie Diethelm, M.D.**



---

**Date**